Glucagon‐Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network
This study supports and establishes the reliability of the original study by (1) producing consistent findings in a range of alternate databases and populations, (2) demonstrating effects for multiple drugs within the GLP-1RA class, and (3) independently confirming the reproducibility of the original study and its findings. This reliability evaluation provides the beginnings of a broader framework for using standardized tools and distributed data networks to systematically interrogate the reliability of findings generated using observational data.
Authors
- Jill Hardin (ORCID: https://orcid.org/0000-0003-2682-2187)
- Christian Reich (ORCID: https://orcid.org/0000-0002-3641-055X)
- Anna Ostropolets (ORCID: https://orcid.org/0000-0002-0847-6682)
- Yasser Albogami (ORCID: https://orcid.org/0000-0002-2816-6526)
- Patrick B. Ryan (ORCID: https://orcid.org/0000-0002-9727-2138)
- Mitchell M. Conover (ORCID: https://orcid.org/0000-0001-5682-3688)
Institutions
- Johnson & Johnson (United States) (US)
- King Saud University (SA)
- IQVIA (United States) (US)
- IQ Solutions (US)
- Columbia University (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/pds.70087
- Citations
- 3
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.67
Funders
- Janssen Research and Development